Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

The agency has yet to make a decision about keeping tirzepatide on or off of its shortage list — letting compound pharmacies ...

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...

The decision to limit Mounjaro injections to 220,000 people is ‘short-sighted and absurd’, says the former prime minister’s ...

Irish Coalition for People Living with Obesity's Susie Birney did say however, that many people in Ireland have seen their ...

Ro today announced it is working with Eli Lilly and Company to streamline access to Zepbound® (tirzepatide) single-dose vials for Ro patients with obesity. The vials will be available as a treatment ...

Losing weight can be a challenge for many. With so many variables present in everyday life, including stress, lack of sleep, ...

With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin ResistanceReallocates ...